Xeris Pharmaceuticals INC: insider trades · United States · SEC (Form 4)

About Xeris Pharmaceuticals INC

Xeris Biopharma Holdings, Inc. (ticker: XERS) is a U.S.-listed biopharmaceutical company trading on the Nasdaq, with headquarters in Chicago, Illinois, United States. For French-speaking investors, Xeris is best understood as a specialty pharma player focused on ready-to-use drug formulations designed to simplify administration, improve usability for patients and caregivers, and reduce some of the practical burdens associated with traditional injectable therapies. The company was originally founded as Xeris Pharmaceuticals, Inc., and its long-term strategy has been built around proprietary formulation platforms, notably XeriSol and XeriJect, which underpin both marketed products and pipeline development programs. Xeris’ business model centers on differentiated specialty pharmaceuticals rather than a broad, diversified large-cap portfolio. The company’s commercial base is currently anchored by three marketed products. Gvoke is a ready-to-use liquid glucagon for severe hypoglycemia. Keveyis is a proven therapy for primary periodic paralysis. Recorlev is used in endogenous Cushing’s syndrome and has been the main growth driver in recent reporting periods. This three-product structure gives the company a more balanced revenue base than a single-asset story, while still leaving meaningful concentration in a small number of specialty indications. From a competitive standpoint, Xeris operates in a niche where formulation science, ease of use, clinical differentiation, and commercial execution matter more than scale alone. The company is not positioned as a broad-spectrum pharmaceutical conglomerate, but as a focused innovator with a clear technology-led identity. Its formulation platforms may also provide optionality for future pipeline expansion and lifecycle management of existing products. Geographically, the company is primarily U.S.-based in terms of headquarters, listing venue, and core commercial footprint, although parts of its history include strategic transactions such as the acquisition of Strongbridge Biopharma. Recent company highlights include strong quarterly performance in 2025 and early 2026, driven in particular by Recorlev growth, along with a patent infringement lawsuit related to Recorlev filed in February 2026. Xeris also issued full-year 2026 guidance in March 2026. Overall, XERS offers investors a mix of specialty pharma growth exposure, product concentration risk, and the usual regulatory and intellectual-property dynamics of the biopharma sector.